Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Summary of Significant Accounting Policies (Tables)

v3.22.4
Nature of Business and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share

The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

Shares issuable upon exercise of stock options

 

 

6,511,910

 

 

 

5,666,267

 

Shares issuable upon exercise of warrants

 

 

796,985

 

 

 

1,594,733

 

Unvested restricted stock awards

 

 

 

 

 

58,333